Laetitia Seguin

Laetitia Seguin

Auto-generated profile, based on publicly available information

Laetitia Seguin

Université Co□te d’Azur, Centre National de la Recherche Scientifique (CNRS) UMR7284, Institut National de la Santé et de la Recherche Médicale (INSERM) U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), Nice 06107, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Trends in Cell Biology
Verified
Journal Article
Closed access
LSLaetitia Seguin
Laetitia Seguin
JDJay S. Desgrosellier
Jay S. Desgrosellier
SWSara M. Weis
Sara M. Weis
DCDavid A. Cheresh
David A. Cheresh

20 April 2014 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LSLaetitia Seguin
Laetitia Seguin
SKShumei Kato
Shumei Kato
AFAleksandra Franovic
Aleksandra Franovic
MCM. Fernanda Camargo
M. Fernanda Camargo
JLJacqueline Lesperance
Jacqueline Lesperance
DCDavid A. Cheresh
David A. Cheresh

1 August 2014 in Developmental Cell
Verified
Journal Article
Closed access
JDJay S. Desgrosellier
Jay S. Desgrosellier
JLJacqueline Lesperance
Jacqueline Lesperance
LSLaetitia Seguin
Laetitia Seguin
MGMaricel Gozo
Maricel Gozo
SKShumei Kato
Shumei Kato
DCDavid A. Cheresh
David A. Cheresh

13 November 2011 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AMAinhoa Mielgo
Ainhoa Mielgo
LSLaetitia Seguin
Laetitia Seguin
MHMiller Huang
Miller Huang
MCMaria Fernanda Camargo
Maria Fernanda Camargo
SASudarshan Anand
Sudarshan Anand
DCDavid A Cheresh
David A Cheresh
Raf kinase activity is deregulated in cancers and is thought to promote tumor growth by inducing proliferation signaling through MEK/Erk. This report identifies a new role for c-Raf independent of MEK/Erk and relying on phosphorylation of Ser338. Phospho–C-Raf interacts with the mitotic kinases Aurora-A and Plk1, activating the latter to promote mitotic progression and increase cell division, and this pathway is a crucial mediator for the protumorigenic effect of c-Raf in vivo. RAF kinases regulate cell proliferation and survival and can be dysregulated in tumors1,2. The role of RAF in cell proliferation has been linked to its ability to activate mitogen-activated protein kinase kinase 1 (MEK) and mitogen-activated protein kinase 1 (ERK). Here we identify a MEK-independent role for RAF in tumor growth. Specifically, in mitotic cells, CRAF becomes phosphorylated on Ser338 and localizes to the mitotic spindle of proliferating tumor cells in vitro as well as in murine tumor models and in biopsies from individuals with cancer. Treatment of tumors with allosteric inhibitors, but not ATP-competitive RAF inhibitors, prevents CRAF phosphorylation on Ser338 and localization to the mitotic spindle and causes cell-cycle arrest at prometaphase. Furthermore, we identify phospho-Ser338 CRAF as a potential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade. Mechanistically, CRAF, but not BRAF, associates with Aurora kinase A (Aurora-A) and Polo-like kinase 1 (Plk1) at the centrosomes and spindle poles during G2/M. Indeed, allosteric or genetic inhibition of phospho-Ser338 CRAF impairs Plk1 activation and accumulation at the kinetochores, causing prometaphase arrest, whereas a phospho-mimetic Ser338D CRAF mutant potentiates Plk1 activation, mitosis and tumor progression in mice. These findings show a previously undefined role for RAF in tumor progression beyond the RAF-MEK-ERK paradigm, opening new avenues for targeting RAF in cancer.

1 January 2009 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
LSLaetitia Seguin
Laetitia Seguin
CLCaroline Liot
Caroline Liot
RMRym Mzali
Rym Mzali
RHRyoko Harada
Ryoko Harada
ASAurelie Siret
Aurelie Siret
JBJacques Bertoglio
Jacques Bertoglio
Rho GTPases are critical for mitosis progression and completion of cytokinesis. During mitosis, the GDP/GTP cycle of Rho GTPases is regulated by the exchange factor Ect2 and the GTPase activating protein MgcRacGAP which associates with the kinesin MKLP1 in the centralspindlin complex. We report here that expression of Ect2, MgcRacGAP, and MKLP1 is tightly regulated during cell cycle progression. These three genes share similar cell cycle-related signatures within their promoter regions: (i) cell cycle gene homology region (CHR) sites located at -20 to +40 nucleotides of their transcription start sites that are required for repression in G(1), (ii) E2F binding elements, and (iii) tandem repeats of target sequences for the CUX1 transcription factor. CUX1 and E2F1 bind these three promoters upon S-phase entry, as demonstrated by chromatin immunoprecipitation, and regulate transcription of these genes, as established using promoter-luciferase reporter constructs and expression of activated or dominant negative transcription factors. Overexpression of either E2F1 or CUX1 increased the levels of the endogenous proteins whereas small interfering RNA knockdown of E2F1 or use of a dominant negative E2F1 reduced their expression levels. Thus, CUX1, E2F, and CHR elements provide the transcriptional controls that coordinate induction of Ect2, MgcRacGAP, and MKLP1 in S phase, leading to peak expression of these interacting proteins in G(2)/M, at the time they are required to regulate cytokinesis.

3 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
SASunil J. Advani
Sunil J. Advani
MCMaria Fernanda Camargo
Maria Fernanda Camargo
LSLaetitia Seguin
Laetitia Seguin
AMAinhoa Mielgo
Ainhoa Mielgo
SASudarshan Anand
Sudarshan Anand
DCDavid A. Cheresh
David A. Cheresh
Although oncology therapy regimens commonly include radiation and genotoxic drugs, tumour cells typically develop resistance to these interventions. Here we report that treatment of tumours with ionizing radiation or genotoxic drugs drives p21-activated kinase 1 (PAK1)-mediated phosphorylation of CRAF on Serine 338 (pS338) triggering a kinase-independent mechanism of DNA repair and therapeutic resistance. CRAF pS338 recruits CHK2, a cell cycle checkpoint kinase involved in DNA repair, and promotes CHK2 phosphorylation/activation to enhance the tumour cell DNA damage response. Accordingly, a phospho-mimetic mutant of CRAF (S338D) is sufficient to induce the CRAF/CHK2 association enhancing tumour radioresistance, while an allosteric CRAF inhibitor sensitizes tumour cells to ionizing radiation or genotoxic drugs. Our findings establish a role for CRAF in the DNA damage response that is independent from its canonical function as a kinase.